Elsevier

Fitoterapia

Volume 115, December 2016, Pages 101-105
Fitoterapia

Cornigerin, a new sesqui-lignan from the hepatoprotective fractions of Cynara cornigera L

https://doi.org/10.1016/j.fitote.2016.09.015Get rights and content

Abstract

The ethanol extract of Cynara cornigera L. was fractionated and the fractions were subjected to hepatoprotective assays using Wistar albino rats at a dose of 500 and 250 mg/kg. The liver injury was induced in rats using carbon tetrachloride. Biochemical parameters such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin were estimated as reflections of the liver condition, with silymarin as a positive control. Phytochemical investigation and chromatographic separation of the hepatoprotective fractions led to the isolation of a new sesqui-lignan namely cornigerin (1), along with eight known compounds: apigenin (2), luteolin (3), β-sitosterol glycoside (4), apigenin 7-O-β-D-glucopyranoside (5), luteolin-7-O-β-D-glucopyranoside (6), apigenin-7-O-rutinoside (7), cynarin 1,5-di-O-caffeoylquinic acid (8), and apigenin-7-O-β-D-glucuronide (9). This is the first report for the isolation of 8 and 9 from this plant.

Introduction

The liver is one of the largest organs in the human body and the main site for intense metabolism and detoxification [1]. Although liver diseases are worldwide problem, it is much more exaggerated in Egypt [2] and in spite of the great advances in modern medicine, no effective medicines are available that could stimulate liver function after damage or help regeneration [3]. Progressive fibrosis occurs after chronic liver injury of any etiology and removing the causative agent is the only effective therapy to stop or even reverse liver fibrosis [4], [5]. Up till now there are no FDA-approved treatments for alcoholic liver disease [6].

Non-alcoholic fatty liver disease (NAFLD) develops when fat builds up within the liver and the mostly affected people are overweight or obese. If the progression of the condition is severe enough, it can lead to liver failure. It is well established that NAFLD is the most common liver disease worldwide with a prevalence rate of 46% in the general population and even a higher rate of 74% among diabetics [7], [8]. NAFLD is strongly associated with insulin resistance and a large portion of NAFLD patients have postprandial hyperinsulinaemia and abnormal glucose tolerance. Recently several studies had proved that NAFLD is an independent strong risk factor for pre-diabetes [9]. A new US study found that nearly one third of children with NAFLD also have prediabetes or type 2 diabetes [10]. Recent studies have shown that silymarin and silibinin appears to be effective in reducing steatosis and insulin resistance [11], [12], [13].

This fact puts a challenge for scientists to explore the potential of hepatoprotective activity of plants based on traditional use where a large number of medicinal preparations are recommended for the treatment of liver disorders [14]. Members of the family Asteraceae especially the tribe Cynareae are known for their efficacy in relieving some liver disorders. In particular Silybum marianum [15], [16], [17], [18], [19], [20] and Cynara scolymus [21], [22], [23] are well known active hepatoprotective agents. Silymarin, obtained from Silybum marianum is a widely used plant derived hepatoprotective agent. Cynareae tribe is represented in Egypt by many genera such as Silybum, Cynara, Centaurea, Carduus, Onopordon and others [24], [25]. Therefore, in an attempt to confront the growing problem of liver diseases in Egypt and worldwide, some plants belonging to the tribe Cynareae growing in Egypt were evaluated for their hepatoprotective activities [26]. Cynara cornigera was found to be active and was selected to carry out a biologically guided fractionation and phytochemical examination of the active fractions.

In the present study, investigation of the hepatoprotective activity of different fractions prepared from the aerial parts of C. cornigera was carried. This was followed by phytochemical investigation of the active fractions which resulted in the isolation of the new sesqui-lignan, 7,8-trans-7′, 8′ -trans- 7″, 8″-cis- 8, 8′- trans-4, 4″, 9, 9″ - tetrahydroxy-3,3′,3″-trimethoxy-4′,8″-5′,7″-dioxy-7,9′-epoxy-lignan-7′-ol (cornigerin). This is the first report of its isolation from nature.

Section snippets

General experimental procedures

Melting points were determined using Gallenkamp, Sanyo, United Kingdom. UV spectra were measured using Pye Unicam SP8-100 UV/VIS spectrophotometer. High Resolution Electrospray Ionization Mass spectrometry (HREIMS) was recorded on Bruker BioApex mass spectrometer. Electron Impact Mass spectroscopy (EI-MS) analysis of compound 1 was performed using MM 7070 E spectrometer. Nuclear magnetic resonance analyses (1H NMR, 13C NMR, DEPT, COSY, HMQC and HMBC) were obtained on a Varian AS 400 MHz

Results and discussion

The UV spectrum of compound 1 in MeOH showed a λmax at 280 nm. The bathochromic shift (14 nm) that occurred upon the addition of dil. NaOH and its colour with FeCl3 indicated the phenolic nature of the compound. The HRESIMS (positive ion mode) showed an [M + Na]+ peak at m/z 593.2012 (calc. 593.1998) and [2 M + Na]+ at m/z 1163.4105 (calc. 1163.4105) suggesting a molecular formula of C30H34O11. The EI-MS showed peaks at m/z 555 (17%) [M-CH3] and m/z 539 (15%) [M-OCH3], confirming the molecular

Conclusion

A new sesqui-lignan along with eight known compounds was isolated from the hepatoprotective fractions of the ethanol extract of Cynara cornigera. The hepatoprotective activity of the isolates is currently underway.

Acknowledgments

The authors thank the Egyptian Government for the partial funding and Dr. Baharthi Avula for HRMS.

References (35)

  • G.T. Strickland

    Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors

    Hepatology

    (2006)
  • R. Bataller et al.

    Hepatic stellate cells as a target for the treatment of liver fibrosis

    Semin. Liver Dis.

    (2001)
  • R. Bataller et al.

    Liver fibrosis

    J. Clin. Invest.

    (2005)
  • T.H. Frazier et al.

    Treatment of alcoholic liver disease

    Ther. Adv. Gastroenterol.

    (2011)
  • R. Ortiz-Lopez et al.

    Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)

    Diabetes Care

    (2012)
  • S. Zelber-Sagi et al.

    Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up

    Liver Int.

    (2013)
  • K.P. Newton et al.

    Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease

    JAMA Pediatr.

    (2016)
  • Cited by (5)

    View full text